Lupus (SLE): vizsgálatok itt: Németország
38 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- No phaseTaking peopleAnifrolumab Malignancy and Serious Infections Study
- Where
- Essen
- Életkor
- 18 év to 130 év
- People
- 3506 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07000110 - 1/2. fázisTaking peopleMB-CART19.1 in refractory SLE
- Where
- Erlangen, Magdeburg, Tuebingen, Wuerzburg
- Életkor
- 18 év and over
- People
- 30
- Run by
- Miltenyi Biomedicine GmbH
See details and how to join2023-507654-33-00 · EU 2023-507654-33-00 - 3. fázisCsak meghívásosLong-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
- Where
- Leipzig, Minden
- Életkor
- 18 év to 75 év
- People
- 680 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00 - 1. fázisTaking peopleA Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
- Where
- Berlin
- Életkor
- 18 év and over
- People
- 20
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2026-526282-25-00 · EU 2026-526282-25-00 - 1. fázisTaking peopleA Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
- Where
- Augsburg, Cologne, Frankfurt Am Main, Hanover, Mainz
- Életkor
- 18 év and over
- People
- 51 worldwide
- Run by
- CRISPR Therapeutics AG
See details and how to join2024-518528-54-00 · EU 2024-518528-54-00 - 3. fázisTaking peopleA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
- Where
- Cologne, Dresden, Heidelberg, Munich
- Életkor
- 18 év to 75 év
- People
- 300 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT07201129 · EU 2025-522984-14-00 - 1. fázisTaking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Berlin, Dresden, Duesseldorf, Hamburg, Kiel
- Életkor
- 18 év and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00 - 1. fázisTaking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Cologne, Duesseldorf, Jena, Mainz
- Életkor
- 18 év to 70 év
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - No phaseTaking peopleLUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
- Where
- Berlin, Dresden, Düsseldorf, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hanover, Heidelberg, Herne, Kiel, Mainz, Munich, Münster
- Életkor
- 18 év and over
- People
- 606
- Run by
- Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05714930 - 1/2. fázisTaking peopleA phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL
- Where
- Erlangen
- Életkor
- 18 év and over
- People
- 12
- Run by
- Universitaetsklinikum Erlangen AöR
See details and how to join2024-519532-16-00 · EU 2024-519532-16-00 - 2/3. fázisTaking peopleA Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- Where
- Berlin, Bochum, Hamburg, Hanover
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Kyverna Therapeutics
See details and how to joinNCT07403188 · EU 2024-511198-31-00 - 1/2. fázisTaking peopleMB-CART19.1 in Refractory SLE
- Where
- Erlangen, Magdeburg, Tübingen
- Életkor
- 18 év and over
- People
- 29
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT06189157 - 1/2. fázisTaking peopleCAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
- Where
- Erlangen
- Életkor
- 18 év and over
- People
- 24
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT06347718 · EU 2024-516819-24-00